Table 2.
Baseline characteristics of the study population
| Characteristics | Values |
|---|---|
| Clinical information | |
| Age (years)† | 54.3 ± 10.1 (30–79) |
| Male/female | 65/12 |
| BMI (kg/m²)† | 23.5 ± 0.32 |
| Etiology of liver disease | |
| Hepatitis B virus | 66 (85.7) |
| Tumor size (cm)† | 3.4 ± 1.7 (1.0-12.7) |
| AFP (≥ 7 ng/mL) | 58 (75.3) |
| AST (≥ 40 IU/L) | 25 (32.5) |
| ALT (≥ 50 IU/L) | 26 (33.8) |
| PIVKA_II (≥ 32.5 mAU/mL) | 40 (51.9) |
| Cirrhosis | 32 (41.6) |
| BCLC stage | |
| 0 | 6 (7.8) |
| A | 62 (80.5) |
| B | 6 (7.8) |
| C | 3 (3.9) |
| Child-Pugh class | |
| A | 70 (90.1) |
| B | 7 (9.9) |
| Pathologic findings | |
| MVI status | |
| MVI negative | 54 (70.1) |
| MVI positive | 23 (29.9) |
| Edmondson-Steiner grade | |
| Grade I | 3 (3.9) |
| Grade II | 47 (61.4) |
| Grade III | 27 (35.1) |
BMI, body mass index; AFP, alpha-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransaminase; PIVKA_II, protein-induced vitamin K absence or antagonist-II; BCLC stage, Barcelona Clinic Liver Cancer stage; MVI, microvascular invasion
Unless indicated otherwise, data represent the number of patients, with percentages in parentheses. †, data are expressed as mean ± standard deviation with ranges in parentheses